TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding the company’s capabilities. TFF also said that it will continue its relationship with the University of Texas at Austin, where it “has extensive early-stage formulation capabilities.”
The company added that it expects to hire additional personnel for its product development team “to support the growing number of partnered projects.” In October 2020, TFF announced that Experic was adding a thin film freezing manufacturing line at its Cranbury, NJ, USA facility, and the company recently announced a partnership with Catalent for scale-up and manufacturing of DPI formulations based on TFF’s thin film freezing technology.
TFF is developing inhaled dry powder vaccines for the US army and has formulated an inhaled mAb against Ebola and a vaccine against equine encephalitis. The company’s pipeline includes niclosamide for COVID-19; Aug-3387 mAb for COVID-19; voriconazole for IPA; and tacrolimus for prevention of organ transplant rejection.
TFF Pharmaceuticals VP of Product Development and Manufacturing John Koleng commented, “The opening of our new Austin R&D facility represents an important evolution of TFF’s operations, reflecting growing demand for our thin film freezing technology and product development services. The Austin facility will enable us to increase testing capacity so that we can run a larger number of feasibility studies, including a focus on biologics where demand has continued to grow. Additionally, as many of our partnered programs move to clinical evaluation, the ability to scale-up manufacturing in parallel becomes mission critical. We expect the new Austin facility will allow us to meet the current growing demand for thin film freezing-based products.”
CEO Glenn Mattes said, “As our internal programs advance and our network of partnerships expands, establishing this additional research space in Austin is a natural next step. . . . We will also continue to work closely with our partners, including Dr. Robert O. Williams, Special Advisor to TFF and Co-Inventor of the thin film freezing technology, who continues to advance new research demonstrating the broad applications and advantages of our technology from his home base at UT Austin.”
Read the TFF Pharmaceuticals press release.
